



# ctos<sup>®</sup>

Connective Tissue Oncology Society

## 2018 Annual Meeting

November 14 - 17, 2018

Rome Cavalieri Hotel • Rome, Italy



### Wednesday, 14 November, 2018

12:00 pm - 6:00 pm	Registration
6:00 pm - 8:00 pm	Welcome Reception

Salon de Cavalieri 1 & Gallery

San Pietro Gallery

### Thursday, 15 November, 2018

6:00 am - 7:00 am	Registration
7:00 am - 8:00 am	Coffee and Posters

Salon de Cavalieri 1 & Gallery

Salon de Cavalieri 1 & Gallery

9:00 am - 11:00 am

– SARC PROGRAM –

Salon del Cavalieri 2,3,4

#### Chawla/Rosenfeld Developmental Therapeutics Symposium

Emerging and Novel Biologically Targeted Approaches for Sarcoma Patients

##### Introduction

**Elizabeth Lawlor, MD, PhD**

**Robert Maki, MD, PhD**

##### Enhancing Activity of B7-H3 CAR T Cells for Pediatric Sarcomas

**Robbie Majzner, MD**

Discussion / Q & A

##### TBD

Discussion / Q & A

##### Epigenetic Changes following the Loss of PRC2 in MPNST: Emerging Therapeutic Opportunities

**Keila Torres, MD, PhD**

Discussion / Q & A

##### 2019 Career Development Update

**Elizabeth Lawlor, MD, PhD**



**SARC**  
collaborating to cure sarcoma

10:30 am - 11:00 am **Morning Coffee Break**

Salon de Cavalieri 1 & Gallery

11:00 am - 11:30 am **OPENING REMARKS**

Salon del Cavalieri 2,3,4

**Sarcoma of the Year: Intimal Sarcoma**

Paper 001

3042623

**SYSTEMIC TREATMENTS IN MDM2 + INTIMAL SARCOMA: A MULTICENTRE EXPERIENCE WITH ANTHRACYCLINE, GEMCITABINE AND PAZOPANIB WITHIN THE WORLD SARCOMA NETWORK (WSN)**

**Anna Maria Frezza**<sup>1</sup>; Tarek Assi<sup>2</sup>; Luigi Mariani<sup>3</sup>; Armelle Dufresne<sup>4</sup>; Siontis Brittany<sup>5</sup>; Kan Yonemori<sup>6</sup>; Emi Noguchi<sup>6</sup>; Eytan Ben-Amy<sup>7</sup>; Mrinal Gounder<sup>8</sup>; Robin Jones<sup>9</sup>; Pawel Teterycz<sup>10</sup>; Florence Duffaud<sup>12</sup>; Maria Abbondanza Pantaleo<sup>11</sup>; Vinod Ravi<sup>13</sup>; Bruno Vincenzi<sup>14</sup>; Giacomo Giulio Baldi<sup>15</sup>; Alexander Fedenko<sup>16</sup>; Hans Gelderblom<sup>17</sup>; Robert Maki<sup>18</sup>; Jean-Yves Blay<sup>4</sup>; Axel Le Cesne<sup>2</sup>; Scott Schuetze<sup>5</sup>; Paolo Casali<sup>1</sup>; Katherine Thornton<sup>7</sup>; Silvia Stacchiotti<sup>1</sup>

<sup>1</sup>Medical Oncology 2, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; <sup>2</sup>Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France; <sup>3</sup>Unit of Clinical Epidemiology and Trial Organization, IRCCS Fondazione Istituto Nazionale Tumori, Milano, Milan, Italy; <sup>4</sup>Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France; <sup>5</sup>Department of Medicine, University of Michigan, Ann Arbor, MI, USA; <sup>6</sup>Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan; <sup>7</sup>Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; <sup>8</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>9</sup>Sarcoma Unit, Royal Marsden NHS Foundation Trust/ Institute of Cancer Research, London, United Kingdom; <sup>10</sup>Maria Skłodowska-Curie Institute-Oncology Center, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland; <sup>11</sup>Sant'Orsola Malpighi Hospital, Department of Specialized, Experimental and Diagnostic Medicine, Bologna, Italy; <sup>12</sup>Department of Oncology, Assistance Publique Hôpitaux de Marseille Timone Hospital, Marseille, France; <sup>13</sup>Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>14</sup>Medical Oncology, University Campus Bio-Medico, Rome, Italy; <sup>15</sup>Medical Oncology, Nuovo Ospedale "S.Stefano", Prato, Italy; <sup>16</sup>Medical Oncology, N.N. Blokhin Russian Cancer Research, Moscow, Russian Federation; <sup>17</sup>Medical Oncology, Leiden University Medical Centre, Leiden, Netherlands; <sup>18</sup>Medical Oncology, Northwell Health and Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

Paper 002

3026957

**PRIMARY MALIGNANT SARCOMAS OF THE HEART AND GREAT VESSELS: A RETROSPECTIVE ANALYSIS OF PRESENTATION, MANAGEMENT AND OUTCOMES**

**Luke Smith**<sup>1</sup>; Han Hsi Wong<sup>2</sup>; Marius Berman<sup>3</sup>; Dochka Davidson<sup>2</sup>; Gail Horan<sup>2</sup>; David Jenkins<sup>3</sup>; Helen Hatcher<sup>2</sup>

<sup>1</sup>School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; <sup>2</sup>Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; <sup>3</sup>Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom

Paper 003

3042337

**CLINICAL "REAL WORLD" NEXT GENERATION SEQUENCING REVEALS UNIQUE ABERRATIONS IN INTIMAL SARCOMA**

**Jason Roszik**; Anthony P. Conley; Roman Groisberg; Vinod Ravi; Roberto Carmagnani Pestana; Shiraj Sen; Vivek Subbiah

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Paper 004

3042847

**OUTCOMES OF MULTIMODALITY TREATMENT WITH INDUCTION CHEMOTHERAPY, MAXIMAL RESECTION, AND PROTON BASED RADIATION THERAPY FOR CARDIAC AND PULMONARY VESSEL SARCOMAS**

**Yen-Lin E. Chen**<sup>1</sup>; Rouyu Miao<sup>1</sup>; Edwin Choy<sup>2</sup>; Gregory M. Cote<sup>2</sup>; Thomas F. DeLaney<sup>1</sup>

<sup>1</sup>Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; <sup>2</sup>Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA

Soft Tissue Sarcoma: Chemotherapy

- Paper 005 3042630  
**THE IMPACT OF CHEMOTHERAPY ON SURVIVAL OF PATIENTS WITH EXTREMITY AND TRUNK WALL SOFT TISSUE SARCOMA: REVISITING THE RESULTS OF THE EORTC-STBSG 62931 RANDOMISED TRIAL USING SARculator, A VALIDATED NOMOGRAM-BASED RISK ASSESSMENT TOOL**  
**Sandro Pasquali**<sup>1</sup>; Sara Pizzamiglio<sup>2</sup>; Nathan Touati<sup>2</sup>; Saskia Litiere<sup>2</sup>; Sandrine Marreaud<sup>2</sup>; Bernd Kasper<sup>3</sup>; Hans Gelderblom<sup>4</sup>; Silvia Stacchiotti<sup>1</sup>; Ian Judson<sup>5</sup>; Angelo P. Dei Tos<sup>6</sup>; Paolo Verderio<sup>1</sup>; Paolo Casali<sup>1</sup>; Penella J. Wolf<sup>7</sup>; Alessandro Gronchi<sup>1</sup>  
<sup>1</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; <sup>2</sup>European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium; <sup>3</sup>University of Heidelberg, Heidelberg, Germany; <sup>4</sup>Leiden University Medical Centre, Leiden, Netherlands; <sup>5</sup>The Royal NHS Foundation Trust, London, United Kingdom; <sup>6</sup>Treviso General Hospital, Treviso, Italy; <sup>7</sup>University of Sheffield, Sheffield, United Kingdom
- Paper 006 3042737  
**PROSPERSITY SCORE MATCHING ANALYSIS OF DOXORUBICIN PLUS DACARBAZINE, DOXORUBICIN PLUS IFOSFAMIDE OR DOXORUBICIN ALONE AS FIRST-LINE TREATMENT FOR ADVANCED, METASTATIC OR UNRESECTABLE LEIOMYOSARCOMA: A RETROSPECTIVE STUDY FROM THE EORTC SOFT TISSUE AND BONE SARCOMA GROUP**  
**Lorenzo D'Ambrosio**<sup>1</sup>; Nathan Touati<sup>2</sup>; Jean-Yves Blay<sup>3</sup>; Tiziana Venesio<sup>4</sup>; Ronan Flippot<sup>17</sup>; Anna M. Czarnecka<sup>5</sup>; Sophie Piperno-Neumann<sup>6</sup>; Javier Martín-Broto<sup>7</sup>; Roberta Sanfilippo<sup>8</sup>; Daniela Katz<sup>9</sup>; Florence Duffaud<sup>10</sup>; Bruno Vincenzi<sup>11</sup>; Bernd Kasper<sup>12</sup>; Daniel P. Stark<sup>13</sup>; Filomena Mazzeo<sup>14</sup>; Armin Tuchscherer<sup>15</sup>; Saskia Litiere<sup>2</sup>; Ward Sents<sup>2</sup>; Silvia Stacchiotti<sup>8</sup>; Hans Gelderblom<sup>16</sup>; Alessandro Gronchi<sup>8</sup>  
<sup>1</sup>Department of Oncology, University of Torino, Torino, Italy; <sup>2</sup>European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; <sup>3</sup>University Claude Bernard Lyon I, Centre Leon Berard, Lyon, France; <sup>4</sup>Medical Oncology - Sarcoma Unit, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy; <sup>5</sup>Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland; <sup>6</sup>Medical Oncology, Institute Curie, Paris, France; <sup>7</sup>Medical Oncology, Virgen del Rocio University Hospital, Institute of Biomedicine Research (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain; <sup>8</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; <sup>9</sup>Assaf Harofeh Medical Center, Zrifin, Israel; <sup>10</sup>Service d'Oncologie Médicale Chu la Timone, Marseille, France; <sup>11</sup>University Campus Bio-Medico of Rome, Roma, Italy; <sup>12</sup>Sarcoma Unit, University of Heidelberg, Mannheim University Medical Center, ITM - Interdisciplinary Tumor Center Mannheim, Mannheim, Germany; <sup>13</sup>St James's Institute of Oncology, Leeds, United Kingdom; <sup>14</sup>Clinique Universitaire Saint-Luc, Institut Roi Albert II, Brussels, Belgium; <sup>15</sup>University Hospital Cologne, Köln, Germany; <sup>16</sup>Leiden University Medical Center, Leiden, Netherlands; <sup>17</sup>Gustave Roussy Cancer Center, Villejuif, France
- Paper 007 3042520  
**PHASE 1B STUDY OF OLARATUMAB PLUS DOXORUBICIN AND IFOSFAMIDE IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA: INITIAL RESULTS**  
**Sebastian Bauer**<sup>1</sup>; Neeta Somaiah<sup>2</sup>; Silvia Stacchiotti<sup>3</sup>; Peter Reichardt<sup>4</sup>; Hector Soto Parra<sup>5</sup>; Rainer Hamacher<sup>1</sup>; Andrew Lithio<sup>6</sup>; Gary Mo<sup>6</sup>; Samuel Ramage<sup>6</sup>; Jonathan Trent<sup>7</sup>  
<sup>1</sup>West German Cancer Center, University of Duisburg-Essen, Essen, Germany; <sup>2</sup>MD Anderson Cancer Center, University of Texas, Houston, TX, USA; <sup>3</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; <sup>4</sup>Helios Klinikum Berlin-Buch, Berlin, Germany; <sup>5</sup>Department of Medical Oncology, Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele, Catania, Italy; <sup>6</sup>Eli Lilly and Company, Indianapolis, IN, USA; <sup>7</sup>Miller School of Medicine/Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

- Paper 008 3042717  
**ANTHRACYCLINE-BASED VERSUS GEMCITABINE-BASED ADJUVANT CHEMOTHERAPY IN FIGO STAGE 1 UTERINE LEIOMYOSARCOMA**  
**Roberta Sanfilippo**<sup>1</sup>; Rosanna Mancari<sup>2</sup>; Sara Manglaviti<sup>1</sup>; Giorgio Bogani<sup>1</sup>; Domenica Lorusso<sup>1</sup>; Elena Fumagalli<sup>1</sup>; Rossella Bertulli<sup>1</sup>; Angelo Paolo Dei Tos<sup>3</sup>; Paola Collini<sup>1</sup>; Francesco Raspagliesi<sup>1</sup>; Nicoletta Colombo<sup>2</sup>; Paolo Casali<sup>1</sup>  
<sup>1</sup>Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; <sup>2</sup>Gynaecology department, IEO, Milan, Italy; <sup>3</sup>General Hospital Treviso, Treviso, Italy
- Paper 009 3042702  
**EUROPEAN PHASE I/II TRASTS TRIAL OF TRABECTEDIN PLUS RADIOTHERAPY IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA (STS): A COLLABORATIVE SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) SARCOMA GROUPS STUDY**  
Javier Martín-Broto<sup>1</sup>; Antonio Lopez-Pousa<sup>2</sup>; Nadia Hindi<sup>1</sup>; Josefina Cruz<sup>3</sup>; Javier Peinado<sup>1</sup>; Carlo Morosi<sup>4</sup>; **Josep Isern Verdun**<sup>2</sup>; Maria Carmen Dolado<sup>5</sup>; Rosa Maria Alvarez Alvarez<sup>5</sup>; Ana Alvarez González<sup>5</sup>; Tiziana Venesio<sup>6</sup>; Marco Gatti<sup>6</sup>; Pablo Luna Fra<sup>7</sup>; Ignacio Alastuey<sup>7</sup>; Jean-Yves Blay<sup>8</sup>; Marie-Pierre Sunyach<sup>8</sup>; Inmaculada Rincon<sup>10</sup>; Alessandro Gronchi<sup>4</sup>; Jesus Romero<sup>9</sup>  
<sup>1</sup>Institute of Biomedicine Research (IBIS)- University Hospital Virgen del Rocio/CSIC/University of Seville, Seville, Spain; <sup>2</sup>Hospital Sant Pau, Barcelona, Spain; <sup>3</sup>University Hospital of Canary Islands , Santa Cruz De Tenerife, Spain; <sup>4</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; <sup>5</sup>University Hospital Gregorio Marañón, Madrid, Spain; <sup>6</sup>Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy; <sup>7</sup>University Hospital Son Espases, Palma de Mallorca, Spain; <sup>8</sup>Centre Léon Bérard, Lyon, France; <sup>9</sup>Hospital Puerta de Hierro, Madrid, Spain; <sup>10</sup>University Hospital Virgen del Rocio, Seville, Spain

4:00 pm - 6:00 pm

– SESSION 3 –

Salon del Cavalieri 2,3,4

**GIST**

- Paper 010 3042567  
**MULTICENTRIC RETROSPECTIVE ANALYSIS OF PATIENTS WITH KIT EXON 9 MUTATED GIST**  
Almudena Callejo Goena<sup>1</sup>; Sara Faouzi<sup>2</sup>; Olivier Bouche<sup>3</sup>; Thomas Chevalier<sup>4</sup>; Nicolas Isambert<sup>5</sup>; Florence Duffaud<sup>4</sup>; Olivier Collard<sup>6</sup>; Nicolas Penel<sup>7</sup>; Olivier Mir<sup>2</sup>; Philippe Terrier<sup>8</sup>; **Jean-Yves Blay**<sup>9</sup>; Axel Le Cesne<sup>2</sup>  
<sup>1</sup>Medical Oncology, Cruces University Hospital, Barakaldo, Bizkaia, Spain; <sup>2</sup>Medical Oncology, Gustave Roussy Institute, Villejuif, France; <sup>3</sup>Digestive Oncology , Chu Robert Debre, Reims, France; <sup>4</sup>Medical Oncology, Chu La Timone and Aix Marseille Universite (Amu), Marseille, France; <sup>5</sup>Department of Early Clinical Trials, Centre Georges-François Leclerc, Dijon, France; <sup>6</sup>Medical Oncology, Institut De Cancérologie De La Loire – Lucien Neuwirth, La Loire, France; <sup>7</sup>Medical Oncology, Oscar Lambret Center, Lille, France; <sup>8</sup>Department Of Pathology, Gustave Roussy Institute, Villejuif, France; <sup>9</sup>Medical Oncology, Centre Leon Berard, Lyon, France
- Paper 011 3041313  
**A WEB-BASED SURVEY OF PERCEIVED COGNITIVE IMPAIRMENTS AND OTHER PATIENT-REPORTED OUTCOMES IN GIST PATIENTS**  
Robert Ferguson<sup>1</sup>; Jessica Manculich<sup>2</sup>; Hsuan Chang<sup>2</sup>; Beth Snitz<sup>3</sup>; Dana Bovbjerg<sup>4</sup>; **Anette Duensing**<sup>5</sup>  
<sup>1</sup>Biobehavioral Oncology Program, UPMC Hillman Cancer Center, Dept. of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; <sup>2</sup>Biobehavioral Oncology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; <sup>3</sup>Dept. of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; <sup>4</sup>Biobehavioral Oncology Program, UPMC Hillman Cancer Center, Dept. of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; <sup>5</sup>Cancer Therapeutics Program, UPMC Hillman Cancer Center, Dept. of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

- Paper 012 3027631  
**AVAPRITINIB IS HIGHLY ACTIVE AND WELL-TOLERATED IN PATIENTS (PTS) WITH ADVANCED GIST DRIVEN BY DIVERSE VARIETY OF ONCOGENIC MUTATIONS IN KIT AND PDGFRA**  
**Michael Heinrich**<sup>1</sup>; Margaret von Mehren<sup>2</sup>; Robin L. Jones<sup>3</sup>; Sebastian Bauer<sup>4</sup>; Yoon-Koo Kang<sup>5</sup>; Patrick Schöffski<sup>6</sup>; Ferry Eskens<sup>7</sup>; Cesar Serrano<sup>8</sup>; Philippe Cassier<sup>9</sup>; Olivier Mir<sup>10</sup>; William D. Tap<sup>11</sup>; Piotr Rutkowski<sup>12</sup>; Jonathan Trent<sup>13</sup>; Shreyaskumar Patel<sup>14</sup>; Sant P. Chawla<sup>15</sup>; Teresa Zhou<sup>16</sup>; Tamieka Lauz<sup>16</sup>; Oleg Schmidt-Kittler<sup>16</sup>; Khalid K. Mamlouk<sup>16</sup>; Beni B. Wolf<sup>16</sup>; Suzanne George<sup>17</sup>  
<sup>1</sup>OHSU Knight Cancer Institute, Portland, OR, USA; <sup>2</sup>Fox Chase Cancer Centre, Philadelphia, PA, USA; <sup>3</sup>Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; <sup>4</sup>University of Duisburg-Essen, Essen, Germany; <sup>5</sup>Asan Medical Centre, Seoul, Korea (the Republic of); <sup>6</sup>University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; <sup>7</sup>Erasmus MC Cancer Institute, Rotterdam, Netherlands; <sup>8</sup>Vall d' Hebron Institute of Oncology, Barcelona, Spain; <sup>9</sup>Centre Léon Bérard, Lyon, France; <sup>10</sup>Institut Gustave Roussy; Edouard Vaillant Villejuif, Villejuif, France; <sup>11</sup>Memorial Sloan Kettering Cancer Centre, New York, NY, USA; <sup>12</sup>Maria Sklodowska-Curie Institute - Oncology Center, Warszawa, Poland; <sup>13</sup>Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA; <sup>14</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>15</sup>Sarcoma Oncology Centre, Santa Monica, CA, USA; <sup>16</sup>Blueprint Medicines Corporation, Cambridge, MA, USA; <sup>17</sup>Dana Farber Cancer Institute, Boston, MA, USA
- Paper 013 3033840  
**INITIAL RESULTS OF PHASE 1 STUDY OF DCC-2618, A BROAD-SPECTRUM KIT AND PDGFRA INHIBITOR, IN PATIENTS (PTS) WITH GASTROINTESTINAL STROMAL TUMOR (GIST) BY NUMBER OF PRIOR REGIMENS**  
**Suzanne George**<sup>3</sup>; Michael Heinrich<sup>10</sup>; Ping Chi<sup>4</sup>; Albiruni Razak<sup>5</sup>; Margaret von Mehren<sup>6</sup>; Michael Gordon<sup>7</sup>; Kristen Ganjoo<sup>2</sup>; Neeta Somaiah<sup>8</sup>; Jonathan Trent<sup>11</sup>; Julie Wolf<sup>9</sup>; Rodrigo Ruiz-Soto<sup>1</sup>; Oliver Rosen<sup>1</sup>; Filip Janku<sup>8</sup>  
<sup>1</sup>Deciphera, Waltham, MA, USA; <sup>2</sup>Stanford University, Palo Alto, CA, USA; <sup>3</sup>Dana-Farber Cancer Institute, Boston, MA, USA; <sup>4</sup>MSKCC, New York, NY, USA; <sup>5</sup>Princess Margaret Cancer Centre, Toronto, ON, Canada; <sup>6</sup>Fox Chase Cancer Center, Philadelphia, PA, USA; <sup>7</sup>Pinnacle Oncology Hematology, Scottsdale, AZ, USA; <sup>8</sup>MDACC, Houston, TX, USA; <sup>9</sup>Biostats Consultants, Denver, CO, USA; <sup>10</sup>OHSU, Portland, OR, USA; <sup>11</sup>University Miami, Miami, FL, USA
- Paper 014 3041747  
**NON-INVASIVE DETECTION OF CTDNA REVEALS INTRATUMOR HETEROGENEITY AND IS ASSOCIATED WITH TUMOR BURDEN IN GASTROINTESTINAL STROMAL TUMOR**  
**Boye Kjetil**<sup>1</sup>; Heidi Namløs<sup>2</sup>; Skyler J. Mishkin<sup>3</sup>; Tale Barøy<sup>2</sup>; Susanne Lorenz<sup>4</sup>; Bodil Bjerkehagen<sup>5</sup>; Eva Stratford<sup>2</sup>; Else Munthe<sup>2</sup>; Brian A. Kudlow<sup>3</sup>; Ola Myklebost<sup>2</sup>; Leonardo A. Meza-Zepeda<sup>2</sup>  
<sup>1</sup>Department of Oncology, Oslo University Hospital, Oslo, Norway; <sup>2</sup>Department of Tumor Biology, Oslo University Hospital, Oslo, Norway; <sup>3</sup>Archer DX, Inc., Boulder, CO, USA; <sup>4</sup>Genomics Core Facility, Oslo University Hospital, Oslo, Norway; <sup>5</sup>Department of Pathology, Oslo University Hospital, Oslo, Norway
- Paper 015 3042824  
**UTILITY OF CIRCULATING TUMOR DNA (CTDNA) IN THE MANAGEMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST): ANALYSIS OF 184 PATIENTS**  
**Junaid Arshad**<sup>1</sup>; Breelyn A. Wilky<sup>1</sup>; Ali Roberts<sup>2</sup>; Becky Nagy<sup>2</sup>; **Jonathan Trent**<sup>1</sup>  
<sup>1</sup>Sarcoma Medical Oncology, Sylvester Comprehensive Cancer Center, Miami, FL, USA; <sup>2</sup>Guardant Health, Redwood City, CA, USA

## Thursday, 15 November, 2018

---

Paper 016

3030004

### CLINICAL VALUE OF CT-DNA IN LOCALIZED AND ADVANCED GIST: CROSS-VALIDATION OF AMPLICON-BASED NGS WITH DD-PCR IN MATCHED TISSUE AND PLASMA SAMPLES

**Cesar Serrano**<sup>1</sup>; Ana Vivancos<sup>5</sup>; Antonio Lopez-Pousa<sup>12</sup>; Judit Matito<sup>5</sup>; Francesco M. Mancuso<sup>5</sup>; Claudia Valverde<sup>11</sup>; Sergi Quiroga<sup>6</sup>; Stefania Landolfi<sup>2</sup>; Sandra Castro<sup>7</sup>; Cristina Dopazo<sup>7</sup>; Ana Sebio<sup>12</sup>; Anna C. Virgili Manrique<sup>12</sup>; Maria M Menso<sup>8</sup>; Javier Martín-Broto<sup>9</sup>; Alfonso Garcia-Valverde<sup>10</sup>; Jordi Rosell<sup>10</sup>; Jonathan A. Fletcher<sup>3</sup>; Suzanne George<sup>4</sup>; Joan Carles<sup>11</sup>; Joaquín Arribas<sup>10</sup>

<sup>1</sup>Preclinical Research Program and Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO); Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain; <sup>2</sup>Pathology, Vall d'Hebron University Hospital, Barcelona, Spain; <sup>3</sup>Pathology, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA; <sup>4</sup>Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; <sup>5</sup>Genomic Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; <sup>6</sup>Radiology, Vall d'Hebron University Hospital, Barcelona, Spain; <sup>7</sup>Surgical Oncology Division, Vall d'Hebron University Hospital, Barcelona, Spain; <sup>8</sup>Radiology, Sant Pau Hospital, Barcelona, Spain; <sup>9</sup>Medical Oncology, Virgen del Rocío Hospital, Sevilla, Spain; <sup>10</sup>Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; <sup>11</sup>Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; <sup>12</sup>Medical Oncology, Sant Pau Hospital, Barcelona, Spain

## Friday, 16 November, 2018

---

6:00 am - 7:00 am

Registration

Salon de Cavalieri 1 & Gallery

7:00 am - 8:00 am

Coffee and Posters

Salon de Cavalieri 1 & Gallery

8:00 am - 10:00 am

– SESSION 4 –

Salon del Cavalieri 2,3,4

### Soft Tissue Sarcoma: Targeted Therapy

Paper 017

3016595

### PROSPECTIVE TRIAL OF CRIZOTINIB (C) IN PATIENTS (PTS) WITH ADVANCED, INOPERABLE INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMFT) WITH AND WITHOUT ALK ALTERATIONS: EORTC PHASE II STUDY 90101 "CREATE"

**Patrick Schöffski**<sup>1</sup>; Jozef Sufliarsky<sup>2</sup>; Hans Gelderblom<sup>3</sup>; Jean-Yves Blay<sup>7</sup>; Sandra Strauss<sup>8</sup>; Silvia Stacchiotti<sup>9</sup>; Piotr Rutkowski<sup>10</sup>; Lars Lindner<sup>11</sup>; Michael Leahy<sup>12</sup>; Antoine Italiano<sup>13</sup>; Maria Debiec-Rychter<sup>14</sup>; Raf Sciot<sup>4</sup>; Sandrine Marreaud<sup>5</sup>; Axelle Nzokirantevye<sup>5</sup>; Agnieszka Wozniak<sup>6</sup>

<sup>1</sup>General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; <sup>2</sup>National Cancer Institute, Bratislava, Slovakia; <sup>3</sup>Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands; <sup>4</sup>Department of Pathology, University Hospitals Leuven, Leuven, Belgium; <sup>5</sup>European Organisation for Research and Treatment of Cancer, Brussels, Belgium; <sup>6</sup>Department of Oncology, KU Leuven, Laboratory of Experimental Oncology, Leuven, Belgium; <sup>7</sup>Université Cl. Bernard Lyon 1, Centre Léon Bérard, Lyon, France; <sup>8</sup>Department of Oncology, University College London Hospitals NHS Trust, London, United Kingdom; <sup>9</sup>Sarcoma Unit, Cancer Medical Department, Fondazione IRCC Istituto Nazionale Tumori, Milan, Italy; <sup>10</sup>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Institute-Oncology Center, Warsaw, Poland; <sup>11</sup>Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; <sup>12</sup>The Christie NHS Foundation Trust, Manchester, United Kingdom; <sup>13</sup>Institut Bergonié, Bordeaux, France; <sup>14</sup>Department of Human Genetics, University Hospitals Leuven, Leuven, Belgium

- Paper 018 3006132  
**ACTIVITY AND SAFETY OF CRIZOTINIB IN PATIENTS WITH ADVANCED CLEAR CELL SARCOMA (CCSA) WITH *MET* ALTERATIONS. EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER PHASE 2 TRIAL 90101 "CREATE"**  
*Patrick Schöffski<sup>1</sup>; Agnieszka Wozniak<sup>2</sup>; Silvia Stacchiotti<sup>3</sup>; Piotr Rutkowski<sup>4</sup>; Jean-Yves Blay<sup>5</sup>; Lars Lindner<sup>8</sup>; Sandra Strauss<sup>9</sup>; Alan Anthoney<sup>12</sup>; Florence Duffaud<sup>14</sup>; Stephan Richter<sup>13</sup>; Raf Sciot<sup>6</sup>; Debiec-Rychter Maria<sup>10</sup>; Sandrine Marreaud<sup>7</sup>; Laurence Collette<sup>7</sup>; Sebastian Bauer<sup>11</sup>*  
<sup>1</sup>General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; <sup>2</sup>Department of Oncology, KULeuven, Laboratory of Experimental Oncology, Leuven, Belgium; <sup>3</sup>Sarcoma Unit, Cancer Medical Department, Fondazione IRCC Istituto Nazionale Tumori, Milan, Italy; <sup>4</sup>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; <sup>5</sup>Université Claude Bernard Lyon Institute, Centre Léon Bérard, Lyon, France; <sup>6</sup>Department of Pathology, University Hospitals Leuven, Leuven, Belgium; <sup>7</sup>European Organisation for Research and Treatment of Cancer, Brussels, Belgium; <sup>8</sup>Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; <sup>9</sup>Department of Oncology, University College London Hospitals NHS Trust, London, United Kingdom; <sup>10</sup>Department of Human Genetics, University Hospitals Leuven, Leuven, Belgium; <sup>11</sup>Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen, Germany; <sup>12</sup>Leeds Institute of Cancer & Pathology, University of Leeds, Leeds, United Kingdom; <sup>13</sup>University Cancer Center/Medical Dept, University Hospital Carl Gustav Carus, Dresden, Germany; <sup>14</sup>Medical oncology Unit, La Timone University Hospital, Marseille, France
- Paper 019 3025592  
**MILADEMETAN, AN ORAL MDM2 INHIBITOR, IN WELL-DIFFERENTIATED/DE-DIFFERENTIATED LIPOSARCOMA: RESULTS FROM A PHASE 1 STUDY IN PATIENTS WITH SOLID TUMORS AND LYMPHOMAS**  
*Mrinal Gounder<sup>1</sup>; Todd M. Bauer<sup>2</sup>; Gary K. Schwartz<sup>3</sup>; Amy M. Weise<sup>4</sup>; Patricia LoRusso<sup>5</sup>; Prasanna Kumar<sup>6</sup>; Shuquan Chen<sup>6</sup>; Jeanne Mendell<sup>6</sup>; Jarema Kochan<sup>6</sup>; Oleg Zernovak<sup>6</sup>; David S. Hong<sup>7</sup>*  
<sup>1</sup>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, USA; <sup>2</sup>Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, USA; <sup>3</sup>Columbia University Medical Center, New York, NY, USA; <sup>4</sup>Karmanos Cancer Institute, Detroit, MI, USA; <sup>5</sup>Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, USA; <sup>6</sup>Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; <sup>7</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Paper 020 3042882  
**PHASE 2 STUDY OF THE CDK4 INHIBITOR ABEMACICLIB IN DEDIFFERENTIATED LIPOSARCOMA**  
*Mark A. Dickson<sup>1</sup>; Sandra D'Angelo<sup>1</sup>; Mrinal Gounder<sup>1</sup>; Mary L. Keohan<sup>1</sup>; Ciara M. Kelly<sup>1</sup>; Ping Chi<sup>1</sup>; Cristina Antonsecu<sup>4</sup>; Jonathan Landa<sup>2</sup>; Li-Xuan Qin<sup>5</sup>; Andrew Koff<sup>6</sup>; Aimee M. Crago<sup>3</sup>; Sam Singer<sup>3</sup>; William D. Tap<sup>1</sup>*  
<sup>1</sup>Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>Radiology, Memorial Sloan Kettering, New York, NY, USA; <sup>3</sup>Surgery, Memorial Sloan Kettering, New York, NY, USA; <sup>4</sup>Pathology, Memorial Sloan Kettering, New York, NY, USA; <sup>5</sup>Biostatistics, Memorial Sloan Kettering, New York, NY, USA; <sup>6</sup>Molecular Biology, Sloan Kettering Institute, New York, NY, USA
- Paper 021 3042818  
**PHASE II STUDY OF ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA**  
*Geraldine OSullivan Coyne<sup>1</sup>; Elad Sharon<sup>2</sup>; Nancy Moore<sup>1</sup>; Robert Meehan<sup>3</sup>; Naoko Takebe<sup>1</sup>; Lamin Juwara<sup>4</sup>; Laurence Rubinstein<sup>2</sup>; William Read<sup>5</sup>; Richard F. Riedel<sup>7</sup>; Priscilla Merriam<sup>8</sup>; James Hu<sup>6</sup>; Melissa Burgess<sup>9</sup>; James Doroshow<sup>1</sup>; Alice Chen<sup>1</sup>*  
<sup>1</sup>Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA; <sup>2</sup>Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, USA; <sup>3</sup>Moderna Therapeutics, Cambridge, MA, USA; <sup>4</sup>National Cancer Institute, Bethesda, MD, USA; <sup>5</sup>Emory Cancer Center, Atlanta, GA, USA; <sup>6</sup>University of Southern California, Los Angeles, CA, USA; <sup>7</sup>Duke University School of Medicine, Durham, NC, USA; <sup>8</sup>Dana Farber Cancer Institute, Boston, MD, USA; <sup>9</sup>UPMC Hillman Cancer Center, Pittsburgh, PA, USA

Paper 022

3033993

**EZH2 INHIBITOR TAZEMETOSTAT (TAZ) INTERIM DATA IN ADULTS AND PEDIATRIC PATIENTS WITH INI1-NEGATIVE SOFT-TISSUE SARCOMAS (STS) INCLUDING EPITHELIOID SARCOMA (ES) (NCT02601950, NCT02601937)**

**Mrinal Gounder**<sup>1</sup>; Patrick Schöffski<sup>2</sup>; Silvia Stacchiotti<sup>3</sup>; Victor Villalobos<sup>4</sup>; Rashmi Chugh<sup>5</sup>; Mark Agulnik<sup>6</sup>; Steven Attia<sup>7</sup>; Tom Wei-Wu Chen<sup>8</sup>; Gupta Abha<sup>9</sup>; Thierry Jahan<sup>10</sup>; Robin Jones<sup>22</sup>; Antoine Italiano<sup>11</sup>; Jean-Yves Blay<sup>12</sup>; Gregory M. Cote<sup>13</sup>; George Demetri<sup>14</sup>; Elizabeth Loggers<sup>15</sup>; Ravin Ratan<sup>16</sup>; Maryam Fouladi<sup>17</sup>; Margaret Macy<sup>18</sup>; Guy Makin<sup>19</sup>; Alicia Clawson<sup>20</sup>; Scott Daigle<sup>20</sup>; Chelsea Mencio<sup>20</sup>; Inbal Sapir<sup>20</sup>; Franck Bourdeaut<sup>21</sup>

<sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; <sup>3</sup>Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; <sup>4</sup>University of Colorado, Denver, CO, USA; <sup>5</sup>Michigan Medicine Comprehensive Cancer Center, Ann Arbor, MI, USA; <sup>6</sup>Northwestern Memorial Hospital, Chicago, IL, USA; <sup>7</sup>Mayo Clinic in Florida, Jacksonville, FL, USA; <sup>8</sup>National Taiwan University Hospital, Taipei City, Japan; <sup>9</sup>Princess Margaret Hospital, Toronto, ON, Canada; <sup>10</sup>University of California, San Francisco, CA, USA; <sup>11</sup>Institut Bergonie, Bordeaux, France; <sup>12</sup>Centre Léon Bérard, Lyon, France; <sup>13</sup>Massachusetts General Hospital, Boston, MA, USA; <sup>14</sup>Dana Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA, USA; <sup>15</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA; <sup>16</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>17</sup>Cincinnati Children's Hospital, Cincinnati, OH, USA; <sup>18</sup>Children's Hospital Colorado, Aurora, CO, USA; <sup>19</sup>University of Manchester, Manchester, United Kingdom; <sup>20</sup>Epizyme, Cambridge, MA, USA; <sup>21</sup>Curie Institute, Paris, France; <sup>22</sup>The Royal Marsden Hospital and Institute for Cancer Research, London, United Kingdom

Paper 023

3029169

**ACTIVITY OF LAROTRECTINIB IN SARCOMA PATIENTS WITH TRK FUSION CANCER**

**Noah Federman**<sup>1</sup>; Daniel Orbach<sup>2</sup>; Shivaani Kummar<sup>3</sup>; Alexander Drilon<sup>4</sup>; Ulrik Lassen<sup>5</sup>; Birgit Geoerger<sup>6</sup>; Cornelis M. van Tillburg<sup>7</sup>; Theodore W. Laetsch<sup>8</sup>; Steven DuBois<sup>9</sup>; Ramamoorthy Nagasubramanian<sup>10</sup>; Neerav Shukla<sup>4</sup>; Michela Casanova<sup>11</sup>; Soledad Gallego<sup>12</sup>; Stefan Bielack<sup>13</sup>; Atrayee Basu-Mallick<sup>14</sup>; Mohamad Farid<sup>15</sup>; Jyoti Patel<sup>16</sup>; Vicki Keedy<sup>17</sup>; Scott Cruickshank<sup>18</sup>; Nora C. Ku<sup>18</sup>; Michael C. Cox<sup>18</sup>; Alberto Pappo<sup>19</sup>; George Demetri<sup>20</sup>; Douglas Hawkins<sup>21</sup>

<sup>1</sup>Departments of Pediatrics and Orthopaedics, Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA, USA; <sup>2</sup>SIREDO Oncology Center, Institut Curie, PSL University, Paris, France; <sup>3</sup>Stanford Cancer Center, Palo Alto, CA, USA; <sup>4</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>5</sup>Rigshospitalet, Copenhagen, Denmark; <sup>6</sup>Gustave Roussy Cancer Center, Villejuif, France; <sup>7</sup>Hopp Children's Cancer Center at the NCT Heidelberg (KITZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany; <sup>8</sup>University of Texas Southwestern Medical Center/Children's Health, Dallas, TX, USA; <sup>9</sup>Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA; <sup>10</sup>Nemours Children's Hospital, Orlando, FL, USA; <sup>11</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; <sup>12</sup>Hospital Universitario Vall d'Hebron, Barcelona, Spain; <sup>13</sup>Olgahospital, Klinikum Stuttgart, Stuttgart, Germany; <sup>14</sup>Thomas Jefferson University, Philadelphia, PA, USA; <sup>15</sup>National Cancer Centre, Singapore, Singapore; <sup>16</sup>University of Chicago, Chicago, IL, USA; <sup>17</sup>Vanderbilt University School of Medicine, Nashville, TN, USA; <sup>18</sup>Loxo Oncology Inc., South San Francisco, CA, USA; <sup>19</sup>St Jude Children's Research Hospital, Memphis, TN, USA; <sup>20</sup>Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; <sup>21</sup>Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

10:00 am - 10:30 am

**Morning Coffee Break**

Salon de Cavalieri 1 & Gallery



10:30 am - 11:00 am	<b>Young Investigator Award Winners</b>	<i>Salon de Cavalieri 1 &amp; Gallery</i>
Paper 036	3035962 <b>SLFN11 IS A SIGNIFICANT DETERMINANT OF PARP INHIBITOR SENSITIVITY IN PEDIATRIC SARCOMAS</b> <b>Jessica Gartrell</b> ; Marcia M. Mellado-Largarde; Jia Xie; Brandon Bianski; Kaley Blankenship; Michael Clay; Armita Bahrami; Sara Federico; Christopher L. Tinkle; Elizabeth Stewart; Anang Shelat St. Jude Children's Research Hospital, Memphis, TN, USA	
Paper 021	3042818 <b>PHASE II STUDY OF ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA</b> Geraldine OSullivan Coyne <sup>1</sup> ; Elad Sharon <sup>2</sup> ; Nancy Moore <sup>1</sup> ; Robert Meehan <sup>3</sup> ; Naoko Takebe <sup>1</sup> ; Lamin Juwara <sup>4</sup> ; <b>Laurence Rubinstein</b> <sup>2</sup> ; William Read <sup>5</sup> ; Richard F. Riedel <sup>7</sup> ; Priscilla Merriam <sup>8</sup> ; James Hu <sup>6</sup> ; Melissa Burgess <sup>9</sup> ; James Doroshov <sup>1</sup> ; Alice Chen <sup>1</sup> <sup>1</sup> Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA; <sup>2</sup> Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, USA; <sup>3</sup> Moderna Therapeutics, Cambridge, MA, USA; <sup>4</sup> National Cancer Institute, Bethesda, MD, USA; <sup>5</sup> Emory Cancer Center, Atlanta, GA, USA; <sup>6</sup> University of Southern California, Los Angeles, CA, USA; <sup>7</sup> Duke University School of Medicine, Durham, NC, USA; <sup>8</sup> Dana Farber Cancer Institute, Boston, MD, USA; <sup>9</sup> UPMC Hillman Cancer Center, Pittsburgh, PA, USA	

11:00 am - 12:00 pm	<b>– HERMAN SUIT LECTURE –</b>	<i>Salon del Cavalieri 1 &amp; Gallery</i>
	<b>Cristina Antonescu</b> (Memorial Sloan Kettering Cancer Center, New York, NY)	

12:00 pm - 1:00 pm	<b>Lunch</b>	<i>Belle Arti &amp; Garden Lobby</i>
--------------------	--------------	--------------------------------------

1:30 pm - 3:30 pm	<b>– SESSION 5 –</b>	<i>Salon del Cavalieri 2,3,4</i>
	<b>Benign and Intermediate Grade Bone/Soft Tissue Lesions</b>	

Paper 024	3042858 <b>RISKFACORS IN TENOSYNOVIAL GIANT CELL TUMOURS OF LARGE JOINTS, EVALUATED IN 30 INTERNATIONAL SARCOMA CENTERS</b> <b>Monique Mastboom</b> ; Emanuela Palmerini; Floortje Verspoor; Anja Rueten-Budde; Silvia Stacchiotti; Eric Staals; Gerard Schaap; Paul Jutte; Will Aston; Andreas Leithner; Dietmar Dammerer; Akihiko Takeuchi; Quirina Thio; Xiaohui Niu; Jay Wunder; Michiel A. van de Sande Orthopaedics oncology, Leiden University Medical Center, Amsterdam, Noord Holland, Netherlands	
-----------	--	--

- Paper 025 3038487  
**POSITIVE ASSOCIATION BETWEEN TUMOR RESPONSE AND PATIENT-REPORTED OUTCOMES IN PHASE 3 ENLIVEN STUDY OF PEXIDARTINIB IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT)**  
Heather L. Gelhorn<sup>1</sup>; Charles Peterfy<sup>2</sup>; Xin Ye<sup>3</sup>; **Rebecca M. Speck**<sup>1</sup>; Emanuela Palmerini<sup>4</sup>; Silvia Stacchiotti<sup>5</sup>; Jayesh Desai<sup>6</sup>; Andrew Wagner<sup>7</sup>; Thierry Alcindor<sup>8</sup>; Kristen Ganjoo<sup>9</sup>; Javier Martín-Broto<sup>10</sup>; Christopher Ryan<sup>11</sup>; Qiang Wang<sup>3</sup>; Dale Shuster<sup>3</sup>; William D. Tap<sup>12</sup>; Hans Gelderblom<sup>13</sup>  
<sup>1</sup>Evidera, Bethesda, MD, USA; <sup>2</sup>Spire Sciences, Inc., Boca Raton, FL, USA; <sup>3</sup>Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; <sup>4</sup>Istituto Ortopedico Rizzoli, Bologna, Italy; <sup>5</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; <sup>6</sup>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; <sup>7</sup>Dana-Farber Cancer Institute, Boston, MA, USA; <sup>8</sup>McGill University, Montreal, QC, Canada; <sup>9</sup>Stanford Cancer Institute, Stanford, CA, USA; <sup>10</sup>Hospital Universitario Virgen del Rocío, Seville, Spain; <sup>11</sup>Oregon Health & Science University, Portland, OR, USA; <sup>12</sup>Memorial Sloan Kettering Cancer Institute, New York, NY, USA; <sup>13</sup>Leiden University Medical Center, Leiden, Netherlands
- Paper 026 3042414  
**PRIMARY VASCULAR TUMORS OF BONE: AN ANALYSIS OF 427 PATIENTS**  
**Marta Sbaraglia**<sup>1</sup>; Alberto Righi<sup>2</sup>; Marco Gambarotti<sup>2</sup>; Dino Gibertoni<sup>3</sup>; Stefania Benini<sup>2</sup>; Piero Picci<sup>2</sup>; Angelo Paolo Dei Tos<sup>1</sup>  
<sup>1</sup>University of Padua, Treviso, Italy; <sup>2</sup>Pathology, IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy; <sup>3</sup>Biomedical and Neuromotor Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy
- Paper 027 3042427  
**PHASE II TRIAL OF PAZOPANIB IN ADVANCED EXTRASKELETAL MYXOID CHONDROSARCOMA. A COLLABORATIVE SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) SARCOMA GROUPS STUDY**  
**Silvia Stacchiotti**<sup>1</sup>; Stefano Ferrari<sup>2</sup>; Antonio Redondo<sup>3</sup>; Emanuela Palmerini<sup>2</sup>; Nadia Hindi<sup>4</sup>; Maria A. Vaz<sup>5</sup>; Anna Maria Frezza<sup>1</sup>; Antonio Gutierrez<sup>6</sup>; Antonio Lopez-Pousa<sup>16</sup>; Tiziana Venesio<sup>7</sup>; Antoine Italiano<sup>8</sup>; Sarah N. Dumont<sup>9</sup>; Jean-Yves Blay<sup>10</sup>; Nicolas Penel<sup>11</sup>; Daniel Bernabeu<sup>12</sup>; Enrique De Alava<sup>13</sup>; Dominique Ranchere-Vince<sup>10</sup>; Gian Paolo Dagrada<sup>1</sup>; Paola Collini<sup>1</sup>; Josefina Cruz<sup>14</sup>; Javier Martín-Broto<sup>15</sup>  
<sup>1</sup>Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; <sup>2</sup>Cancer Medicine, Istituto Ortopedico Rizzoli, Bologna, Italy; <sup>3</sup>Cancer Medicine, La Paz Institute for Health Research, Madrid, Spain; <sup>4</sup>University Hospital Virgen del Rocío, Sevilla, Spain; <sup>5</sup>Hospital Universitario Ramón y Cajal, Cajal, Spain; <sup>6</sup>Hospital Universitari Son Espases, Palma, Spain; <sup>7</sup>Cancer Medicine, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy; <sup>8</sup>Institut Bergonie, Bordeaux, France; <sup>9</sup>Cancer Medicine, Goussier Roussey, Villejuif, France; <sup>10</sup>Centre Léon Bérard, Lyon, France; <sup>11</sup>Centre Oscar Lambret, Lille, France; <sup>12</sup>Radiology, University Hospital La Paz, Madrid, France; <sup>13</sup>Institute of Biomedicine of Sevilla, Sevilla, Spain; <sup>14</sup>University Hospital of Canarias, Tenerife, Spain; <sup>15</sup>Sant Pau Hospital, Barcelona, Spain
- Paper 028 3042598  
**LONGITUDINAL DISTRESS ASSESSMENT AND RESPONSE TOOL (DART) SCREENING IN ADULTS WITH AGGRESSIVE FIBROMATOSIS: HIGH PREVALENCE OF PERSISTENT EMOTIONAL DISTRESS**  
**Abha Gupta**<sup>1</sup>; Nicole Byers<sup>1</sup>; Sally Burtenshaw<sup>2</sup>; Katrina Ingley<sup>2</sup>; Carol Swallow<sup>2</sup>; Savtaj Brar<sup>2</sup>; Anthony M. Griffin<sup>2</sup>; Peter Ferguson<sup>2</sup>; Jay Wunder<sup>2</sup>; Albiruni Razak<sup>1</sup>; Rebecca Gladly<sup>2</sup>; Roberta Klein<sup>3</sup>; Madeline Li<sup>3</sup>  
<sup>1</sup>Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada; <sup>2</sup>Surgery, Mount Sinai Hospital, Toronto, ON, Canada; <sup>3</sup>Psychiatry, Princess Margaret Cancer Center, Toronto, ON, Canada
- Paper 029 3042617  
**CAN WAIT AND SEE BE THE STANDARD OF CARE FOR INITIAL APPROACH TO PRIMARY SPORADIC DESMOID TUMORS? PRELIMINARY DATA FROM AN ITALIAN SARCOMA GROUP PROSPECTIVE STUDY**  
**Chiara Colombo**<sup>1</sup>; Marco Fiore<sup>1</sup>; Tiziana Venesio<sup>2</sup>; Erica Palesandro<sup>2</sup>; Paola Boccone<sup>2</sup>; Lorenzo D'Ambrosio<sup>2</sup>; Alba Bianco<sup>1</sup>; Paola Collini<sup>1</sup>; Elena Palassini<sup>1</sup>; Silvia Stacchiotti<sup>1</sup>; Angelo Paolo Dei Tos<sup>3</sup>; Paolo Casali<sup>1</sup>; Federica Perrone<sup>1</sup>; Alessandro Gronchi<sup>1</sup>  
<sup>1</sup>Fondazione IRCCS Istituto Tumori Milano, Milan, Italy; <sup>2</sup>IRCCS Istituto Candiolo, Torino, Italy; <sup>3</sup>Ospedale di Treviso, Treviso, Italy

Paper 030 3042719  
**INCORPORATION OF CTNNB1 MUTATION STATUS INTO A PRE-OPERATIVE DESMOID LOCAL RECURRENCE NOMOGRAM IMPROVES PREDICTIVE VALUE**  
*Iris Wei<sup>1</sup>; Anthony Villano<sup>1</sup>; Andrea Knezevic<sup>2</sup>; Bhumika Jadeja<sup>1</sup>; Li-Xuan Qin<sup>2</sup>; Meera Hameed<sup>3</sup>; Sam Singer<sup>1</sup>; **Aimee M. Crago<sup>1</sup>***  
<sup>1</sup>Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>3</sup>Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3:30 pm - 4:00 pm

**Afternoon Coffee Break**

Salon de Cavalieri 1 & Gallery

4:00 pm - 6:00 pm

– SESSION 6 –

Salon del Cavalieri 2,3,4

**Ewing Sarcoma**

Paper 031 3027408  
**EASY-TO-USE PRACTICAL CLINICAL TOOL FOR SURVIVAL ESTIMATION IN EWING SARCOMA AT DIAGNOSIS AND AFTER SURGERY**  
**Sarah E. Bosma<sup>1</sup>**; Carlo Lancia<sup>2</sup>; Anja J. Rüten-Budde<sup>2</sup>; Andreas Ranft<sup>3</sup>; Hans Gelderblom<sup>4</sup>; Marta Fiocco<sup>2</sup>; Michiel A. van de Sande<sup>1</sup>; Sander Dijkstra<sup>1</sup>; Uta Dirksen<sup>3</sup>  
<sup>1</sup>Orthopedics, Leiden University Medical Center, Leiden, Netherlands; <sup>2</sup>Mathematical Institute, Leiden University, Leiden, Netherlands; <sup>3</sup>Pediatrics III, University Hospital Essen, University Duisburg-Essen, Sarcoma Center, West German Cancer Center, Essen, Germany; <sup>4</sup>Medical Oncology, Leiden University Medical Center, Leiden, Netherlands

Paper 032 3042243  
**RETROSPECTIVE ANALYSIS OF USE OF WHOLE LUNG IRRADIATION FOR PATIENTS WITH NEWLY DIAGNOSED EWING SARCOMA AND PULMONARY METASTASES**  
*Hadeel Halalsheh<sup>1</sup>; Sue Kaste<sup>2</sup>; Matthew J. Krasin<sup>3</sup>; April Sykes<sup>4</sup>; Natasha Sahr<sup>4</sup>; Sheri Spunt<sup>5</sup>; Sara Federico<sup>1</sup>; Alberto Pappo<sup>1</sup>; **Michael W. Bishop<sup>1</sup>***  
<sup>1</sup>Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA; <sup>2</sup>Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, USA; <sup>3</sup>Radiation Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA; <sup>4</sup>Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA; <sup>5</sup>Pediatrics - Hematology/Oncology, Lucile Packard Children's Hospital Stanford, Palo Alto, CA, USA

Paper 033 3042780  
**WHOLE-LUNG IRRADIATION AFTER HIGH-DOSE BUSULFAN/MELPHALAN CONDITIONING THERAPY IN EWING SARCOMA WITH LUNG METASTASES: A MULTICENTRIC STUDY**  
**Massimo E. Abate<sup>1</sup>**; Letizia Ronchi<sup>2</sup>; Barbara Diletto<sup>14</sup>; Lorenza Gandola<sup>14</sup>; Nadia Puma<sup>15</sup>; Angela Tamburini<sup>3</sup>; Maurizio Mascarini<sup>4</sup>; Elisa Coassin<sup>4</sup>; Arcangelo Prete<sup>5</sup>; Sebastian Asaftei<sup>6</sup>; Carla Manzitti<sup>7</sup>; Luca Coccoli<sup>8</sup>; Mariella Capasso<sup>9</sup>; Tiziana Venesio<sup>13</sup>; Emilia Pecori<sup>14</sup>; Marta Pierobon<sup>16</sup>; Anna Paioli<sup>1</sup>; Elisa Carretta<sup>10</sup>; Giovanni Piero Frezza<sup>11</sup>; Alessio Giuseppe Morganti<sup>2</sup>; Stefano Ferrari<sup>1</sup>; Piero Picci<sup>12</sup>; Alessandra Longhi<sup>1</sup>; Silvia Cammelli<sup>2</sup>; Roberto Luksch<sup>15</sup>  
<sup>1</sup>Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy; <sup>2</sup>Radiotherapy, Sant'Orsola Hospital, Bologna, Italy; <sup>3</sup>Pediatric Oncoematology, Hospital Meyer, Firenze, Italy; <sup>4</sup>Radiotherapy, CRO Aviano, Aviano, Italy; <sup>5</sup>Pediatric Oncoematology, Sant'Orsola Hospital, Bologna, Italy; <sup>6</sup>Pediatric Oncoematology, OIRM Sant'ANNA, Torino, Italy; <sup>7</sup>Pediatric Oncology, Gaslini Hospital, Genova, Italy; <sup>8</sup>Pediatric Oncoematology, AOUP Pisa, Pisa, Italy; <sup>9</sup>Pediatric Oncology, AORN Santobono-Pausillipon, Napoli, Italy; <sup>10</sup>Statistics, Istituto Ortopedico Rizzoli, Bologna, Italy; <sup>11</sup>Radiotherapy, AUSL Bologna, Bologna, Italy; <sup>12</sup>Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy; <sup>13</sup>Medical Oncology, Istituto Candiolo, Torino, Italy; <sup>14</sup>Radiotherapy, Fondazione IRCCS ISTITUTO NAZIONALE TUMORI, Milano, Italy; <sup>15</sup>Pediatric Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; <sup>16</sup>Pediatric Oncoematology, Azienda Ospedaliera di Padova, Padova, Italy

- Paper 034 3042627  
**THE WNT-DEPENDENT SECRETOME ALTERS TUMOR: TUMOR MICROENVIRONMENT CROSSTALK TO PROMOTE INVASION AND ANGIOGENESIS IN EWING SARCOMA**  
*Allegra Hawkins; Elisabeth Pedersen; Sonja Konzen; Colin Sperring; Sydney Treichel; **Elizabeth Lawlor***  
University of Michigan, Ann Arbor, MI, USA
- Paper 035 3042245  
**A PHASE I STUDY OF THE POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITOR, NIRAPARIB (NIR), IN COMBINAITON WITH IRINOTECAN (IRN) IN PATIENTS WITH ADVANCED EWING SARCOMA: RESULTS OF SARCO25 ARM 2**  
**Sandra J. Strauss**<sup>1</sup>; Karla V Ballman<sup>2</sup>; Kam Zaki<sup>1</sup>; Lee Helman<sup>3</sup>; Brigitte Widemann<sup>4</sup>; Douglas Hawkins<sup>5</sup>; Leo Mascarenhas<sup>3</sup>; J.W Glod<sup>4</sup>; Jay Ji<sup>6</sup>; Ziping Zhang<sup>6</sup>; Birgit Georger<sup>7</sup>; Jeremy Whelan<sup>1</sup>; Denise Reinke<sup>8</sup>; Shreyaskumar Patel<sup>9</sup>; Rashmi Chugh<sup>10</sup>  
<sup>1</sup>University College London Hospitals NHS Trust, London, United Kingdom; <sup>2</sup>Weill Cornell Medicine, New York, NY, USA; <sup>3</sup>Children's Center for Cancer and Blood Diseases, Los Angeles, CA, USA; <sup>4</sup>National Cancer Institute Centre for Cancer Research, Bethesda, MD, USA; <sup>5</sup>Seattle Children's Hospital, Seattle, OR, USA; <sup>6</sup>National Clinical Target Validation Laboratory, Bethesda, MD, USA; <sup>7</sup>Institut Gustave Roussy, Paris, France; <sup>8</sup>SARC, Ann Arbor, MI, USA; <sup>9</sup>MD Anderson, Houston, TX, USA; <sup>10</sup>University of Michigan, Ann Arbor, MI, USA
- Paper 036 3035962  
**SLFN11 IS A SIGNIFICANT DETERMINANT OF PARP INHIBITOR SENSITIVITY IN PEDIATRIC SARCOMAS**  
**Jessica Gartrell**; Marcia M. Mellado-Largarde; Jia Xie; Brandon Bianski; Kaley Blankenship; Michael Clay; Armita Bahrami; Sara Federico; Christopher J. Tinkle; Elizabeth Stewart; Anang Shelat  
St. Jude Children's Research Hospital, Memphis, TN, USA
- Paper 037 3027426  
**INNOVATIVE TARGETED THERAPY FOR EWING SARCOMA**  
**Shunya Ohmura**<sup>1</sup>; Martin F. Orth<sup>1</sup>; Aruna Marchetto<sup>1</sup>; Stefanie Stein<sup>1</sup>; Julia S. Gerke<sup>1</sup>; Giuseppina Sannino<sup>1</sup>; Julian Musa<sup>1</sup>; Fabienne Wehweck<sup>1</sup>; Maximilian M. Knott<sup>1</sup>; Jing Li<sup>1</sup>; Tilman Hölting<sup>1</sup>; Laura Romero-Pérez<sup>1</sup>; Florencia Cidre-Aranaz<sup>1</sup>; Horacio Bach<sup>2</sup>; Wolfgang Hartmann<sup>3</sup>; Uta Dirksen<sup>4</sup>; Thomas Kirchner<sup>5</sup>; Thomas G. Grünewald<sup>6</sup>  
<sup>1</sup>Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany; <sup>2</sup>Department of Medicine, Division of Infectious Diseases, University of British Columbia, Vancouver, BC, Canada; <sup>3</sup>Gerhard-Domagk Institute of Pathology, University Hospital of Muenster, Muenster, Germany; <sup>4</sup>Division of Hematology and Oncology, Department of Pediatrics III, West German Cancer Centre, University Hospital Essen, Essen, Germany; <sup>5</sup>Institute of Pathology, Faculty of Medicine, LMU Munich, German Cancer Research Center (DKFZ), Heidelberg, German Cancer Consortium (DKTK), partner site Munich, Munich, Germany; <sup>6</sup>Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, German Cancer Research Center (DKFZ), Heidelberg, German Cancer Consortium (DKTK), partner site Munich, Munich, Germany

7:00 am - 8:00 am **Coffee and Posters**

Salon de Cavalieri 1 & Gallery

8:00 am - 9:00 am **Poster Discussion**

Salon del Cavalieri 2,3,4

9:00 am - 10:30 am

– SESSION 7 –

Salon del Cavalieri 2,3,4

**Osteosarcoma/Chondrosarcoma/Chordoma**

- Paper 038 3042790  
**STRESS MEDIATED TRANSLATIONAL CONTROL OF CHILDHOOD BONE SARCOMA METASTASIS**  
Amal M. EL-Naggar<sup>1</sup>; Syam Somasekharan<sup>2</sup>; Hongwei Cheng<sup>2</sup>; Gian Luca Negri<sup>3</sup>; Didier Surdez<sup>4</sup>; Olivier Delattre<sup>4</sup>; **Poul H. Sorensen**<sup>1</sup>  
<sup>1</sup>Molecular Oncology, BC Cancer & University of British Columbia, Vancouver, BC, Canada; <sup>2</sup>Vancouver Prostate Centre, Vancouver, BC, Canada; <sup>3</sup>Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada; <sup>4</sup>Centre de recherche de l'Institut Curie, Paris, France
- Paper 039 3035462  
**PROSPECTIVE PHASE II STUDY OF SCANNED BEAM PROTON THERAPY FOR SPINE SARCOMAS**  
**David J. Konieczkowski**<sup>1</sup>; Yen-Lin E. Chen<sup>1</sup>; Karen De Amorim Bernstein<sup>1</sup>; Beow Yeap<sup>2</sup>; Matthew DiMaria<sup>3</sup>; Wenquin Jiang<sup>2</sup>; Nannette Thomas<sup>1</sup>; Suzanne L. McGovern<sup>4</sup>; John T. Mullen<sup>5</sup>; Joseph H. Schwab<sup>6</sup>; Francis Hornicek<sup>7</sup>; Thomas F. DeLaney<sup>1</sup>  
<sup>1</sup>Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; <sup>2</sup>Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA; <sup>3</sup>Cancer Center Protocol Office, Massachusetts General Hospital, Boston, MA, USA; <sup>4</sup>Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA; <sup>5</sup>Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA; <sup>6</sup>Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA; <sup>7</sup>Department of Orthopaedic Surgery, University of California Los Angeles, Los Angeles, MA, USA
- Paper 040 2993960  
**APATINIB FOR ADVANCED OSTEOSARCOMA AFTER FAILURE OF STANDARD MULTIMODAL THERAPY: AN OPEN LABEL PHASE 2 CLINICAL TRIAL(NCT02711007)**  
**Lu Xie**; Jie Xu; Xin Sun; Xiaodong Tang; Taiqiang Yan; Rongli Yang; Wei Guo  
Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China
- Paper 041 3042511  
**SARC024: REGORAFENIB IN PATIENTS WITH REFRACTORY OSTEOSARCOMA**  
**Lara E. Davis**<sup>1</sup>; Christopher Ryan<sup>1</sup>; John Crowley<sup>2</sup>; Kristen Ganjoo<sup>3</sup>; Elizabeth Loggers<sup>4</sup>; Sant P. Chawla<sup>5</sup>; Mark Agulnik<sup>6</sup>; Michael B. Livingston<sup>7</sup>; Damon Reed<sup>8</sup>; Vicki Keedy<sup>9</sup>; Daniel A. Rushing<sup>10</sup>; Scott Okuno<sup>11</sup>; Denise Reinke<sup>12</sup>; Richard F. Riedel<sup>13</sup>; Steven Attia<sup>14</sup>; Leo Mascarenhas<sup>15</sup>; Robert Maki<sup>16</sup>  
<sup>1</sup>Oregon Health and Science University, Portland, OR, USA; <sup>2</sup>Cancer Research and Biostatistics, Seattle, WA, USA; <sup>3</sup>Stanford Cancer Institute, Stanford, CA, USA; <sup>4</sup>Seattle Cancer Care Alliance, Seattle, WA, USA; <sup>5</sup>Sarcoma Oncology Research Center, Santa Monica, CA, USA; <sup>6</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, USA; <sup>7</sup>Levine Cancer Institute, Atrium Health, Charlotte, NC, USA; <sup>8</sup>H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; <sup>9</sup>Vanderbilt University Medical Center, Nashville, TN, USA; <sup>10</sup>Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA; <sup>11</sup>Mayo Clinic, Rochester, MN, USA; <sup>12</sup>SARC, Ann Arbor, MI, USA; <sup>13</sup>Duke University Medical Center, Durham, NC, USA; <sup>14</sup>Mayo Clinic, Jacksonville, FL, USA; <sup>15</sup>Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Univ. of Southern California, Los Angeles, CA, USA; <sup>16</sup>Monter Cancer Center, Northwell Health and Cold Spring Harbor Laboratory, Lake Success, NY, USA

Paper 042 3042857  
**CABOZANTINIB IN PATIENTS WITH ADVANCED OSTEOSARCOMAS AND EWING SARCOMAS: A FRENCH SARCOMA GROUP (FSG)/ US NATIONAL CANCER INSTITUTE PHASE II COLLABORATIVE STUDY**  
**Antoine Italiano<sup>1</sup>**; Nicolas Penel<sup>2</sup>; Emmanuelle Bompas<sup>3</sup>; Sophie Piperno-Neumann<sup>4</sup>; Marina Pulido<sup>1</sup>; Natacha Entz-Werle<sup>5</sup>; Axel Le Cesne<sup>6</sup>; Christine Chevreau<sup>7</sup>; Florence Duffaud<sup>8</sup>; Isabelle Ray-Coquard<sup>9</sup>; Maud Toulmonde<sup>1</sup>; Carine Bellera<sup>1</sup>; Jean-Yves Blay<sup>9</sup>  
<sup>1</sup>Institut Bergonié, Bordeaux, France; <sup>2</sup>Centre Oscar Lambret, Lille, France; <sup>3</sup>Institut Cancerologie de l'Ouest, Nantes, France; <sup>4</sup>Institut Curie, Paris, France; <sup>5</sup>CHU de Strasbourg, Strasbourg, France; <sup>6</sup>Institut Gustave Roussy, Villejuif, France; <sup>7</sup>Oncopole Toulouse, Toulouse, France; <sup>8</sup>APHM Marseille, Marseille, France; <sup>9</sup>Centre Leon Berard, Lyon, France

10:30 am - 11:00 am **Morning Coffee Break** Salon de Cavalieri 1 & Gallery

11:00 am - 12:00 pm – NINA AXELRAD LECTURE – Salon del Cavalieri 2,3,4  
**Jean-Yves Blay**  
(Centre Léon BERARD Lyon, France)

12:00 pm - 1:00 pm **Lunch** Belle Arti & Garden Lobby

1:00 pm - 1:30 pm **Liddy Shriver Early Career Research Award** Salon del Cavalieri 2,3,4

1:30 pm - 3:30 pm – SESSION 8 – Salon del Cavalieri 2,3,4  
**Soft Tissue Sarcoma: Biology**

Paper 043 3042288  
**WHOLE GENOME SEQUENCING OF 1,111 SARCOMA PROBANDS REVEALS POT-1 AS A SARCOMA PREDISPOSITION GENE**  
**Mandy L. Ballinger<sup>1</sup>**; Mark Pinese<sup>1</sup>; Emma Rath<sup>1</sup>; Paul James<sup>2</sup>; Ajay Puri<sup>3</sup>; Nicolas Isambert<sup>4</sup>; Martin Tattersall<sup>5</sup>; Beatrice Seddon<sup>6</sup>; Ian Judson<sup>7</sup>; Winette van der Graaf<sup>7</sup>; Nicolas Penel<sup>8</sup>; Axel Lecesne<sup>9</sup>; Coonoor Chandrasekar<sup>10</sup>; Jean-Emmanuel Kurtz<sup>11</sup>; Joshua Schiffman<sup>12</sup>; R. Lor Randall<sup>12</sup>; Florence Duffaud<sup>13</sup>; Jin-Hee Ahn<sup>14</sup>; Rory Rickard<sup>15</sup>; Jean-Yves Blay<sup>16</sup>; Isabelle Ray-Coquard<sup>16</sup>; David M. Thomas<sup>1</sup>  
<sup>1</sup>Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia; <sup>2</sup>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; <sup>3</sup>Tata Memorial Hospital, Mumbai, India; <sup>4</sup>Centre Georges Francois Leclerc, Dijon, France; <sup>5</sup>University of Sydney, Sydney, New South Wales, Australia; <sup>6</sup>University College Hospital, London, United Kingdom; <sup>7</sup>The Royal Marsden NHS Foundation Trust, London, United Kingdom; <sup>8</sup>Centre Oscar Lambret, Lille, France; <sup>9</sup>Institut Gustav Roussy, Villejuif, France; <sup>10</sup>Royal Liverpool and Broadgreen University Hospital, Liverpool, United Kingdom; <sup>11</sup>Hopitaux Universitaires de Strasbourg, Strasbourg, France; <sup>12</sup>Huntsman Cancer Institute, Salt Lake City, UT, USA; <sup>13</sup>La Timone University Hospital, Marseille, France; <sup>14</sup>Asan Medical Centre, Seoul, Korea (the Republic of); <sup>15</sup>Derriford Hospital, Plymouth, United Kingdom; <sup>16</sup>Centre Leon Berard, Lyon, France

Paper 044 3042786  
**SEQCOMPLEX UNRAVELLING OMICS LANDSCAPE AND TARGETING ONCOGENIC PATHWAYS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS - AN INTEGRATED APPROACH**  
**Maud Toulmonde<sup>1</sup>**; Damien Geneste<sup>1</sup>; Stephanie Verbeke<sup>1</sup>; Julien Adam<sup>2</sup>; Fabiola Cecchi<sup>3</sup>; Banafshe Larijani<sup>4</sup>; Francois Bertucci<sup>6</sup>; Florent Petitprez<sup>5</sup>; Audrey Laroche<sup>1</sup>; Carlo Lucchesi<sup>1</sup>; Antoine Italiano<sup>1</sup>; Todd Hembrough<sup>3</sup>  
<sup>1</sup>Institut Bergonié, Bordeaux, France; <sup>2</sup>Gustave Roussy, Villejuif, France; <sup>3</sup>Nantomics, Rockville, MD, USA; <sup>4</sup>Fastbase Solutions Ltd, Plentzia, Spain; <sup>5</sup>UMRS 1138 - Centre de Recherche des Cordeliers, Paris, France; <sup>6</sup>Institut Paoli Calmettes, Marseille, France

Paper 045 3010210  
**RATIONALES FOR TARGETING/CO-TARGETING LEIOMYOSARCOMA PATHWAYS: BIOLOGIC PROFILES IN 712 UTERINE OR SOFT-TISSUE LMS**  
**Inga-Marie Schaefer**<sup>1</sup>; Elizabeth G. Demicco<sup>2</sup>; Magdalena Matusiak<sup>3</sup>; Sebastian Bauer<sup>4</sup>; Frédéric Chibon<sup>5</sup>; Davis Ingram<sup>6</sup>; Jason L. Hornick<sup>1</sup>; Wei-Lien Wang<sup>6</sup>; Alexander J. Lazar<sup>6</sup>; Matt van de Rijn<sup>3</sup>; Jonathan A. Fletcher<sup>1</sup>  
<sup>1</sup>Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; <sup>2</sup>Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; <sup>3</sup>Department of Pathology, Stanford University Medical Center, Stanford, CA, USA; <sup>4</sup>Department of Medical Oncology, West German Cancer Center, Essen, Germany; <sup>5</sup>Centre de Recherches en Cancérologie de Toulouse, Toulouse, France; <sup>6</sup>Departments of Pathology & Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Paper 046 3042897  
**CHROMATIN STATE TRANSITIONS ASSOCIATED WITH PRC2 FUNCTIONAL LOSS DRIVE A DE-DIFFERENTIATED PHENOTYPE IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS**  
**Veena Kochat**<sup>1</sup>; Ayush Raman<sup>2</sup>; Sharon Landers<sup>1</sup>; Christopher Terranova<sup>2</sup>; Chia-Chin Wu<sup>2</sup>; Xizeng Mao<sup>2</sup>; Davis Ingram<sup>3</sup>; Zachary Mulder<sup>1</sup>; Michelle Yeagley<sup>1</sup>; Hannah Beird<sup>2</sup>; Angela Bhalla<sup>1</sup>; John Slopis<sup>4</sup>; Ian McCutcheon<sup>5</sup>; Jianhua Zhang<sup>2</sup>; Phillip Futreal<sup>2</sup>; Wei-Lien Wang<sup>3</sup>; Alexander J. Lazar<sup>3</sup>; Kunal Rai<sup>2</sup>; Kiela E. Torres<sup>1</sup>  
<sup>1</sup>Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA; <sup>2</sup>Genomic Medicine Department, MD Anderson Cancer Center, Houston, TX, USA; <sup>3</sup>Pathology, MD Anderson Cancer Center, Houston, TX, USA; <sup>4</sup>NeuroOncology Department, MD Anderson Cancer Center, Houston, TX, USA; <sup>5</sup>NeuroSurgery Department, MD Anderson Cancer Center, Houston, TX, USA

Paper 047 3042069  
**TWIST BRIDGES P53 AND MDM2 AND REDUCES THE EFFICACY OF MDM2 INHIBITORS**  
Sara Piccinin<sup>1</sup>; Elena Doriguzzi Breatta<sup>1</sup>; Sara Lombardi<sup>1</sup>; Mattia Lombardi<sup>1</sup>; Flavia Pivetta<sup>1</sup>; Michela Armellini<sup>1</sup>; Camillo Rosano<sup>2</sup>; **Roberta Maestro**<sup>1</sup>  
<sup>1</sup>CRO Aviano, Aviano, Italy; <sup>2</sup>San Martino National Cancer Institute, Genova, Italy

3:30 pm - 4:00 pm **Afternoon Coffee Break** *Salon de Cavalieri 1 & Gallery*

4:00 pm - 5:30 pm **– SESSION 9 –** *Salon del Cavalieri 2,3,4*  
**Soft Tissue Sarcoma: Local Therapy**

Paper 048 3042386  
**LONG-TERM COMPARISON OF LOCAL RECURRENCE AFTER CONVENTIONAL AND INTENSITY-MODULATED RADIATION THERAPY FOR PRIMARY SOFT TISSUE SARCOMAS OF THE EXTREMITY**  
**Joanna C. Yang**<sup>1</sup>; Michael Folkert<sup>2</sup>; Aimee M. Crago<sup>3</sup>; Sam S. Yoon<sup>3</sup>; Sam Singer<sup>3</sup>; Kaled Alektiar<sup>1</sup>  
<sup>1</sup>Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA; <sup>3</sup>Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

- Paper 049 3028760  
**CAN WE CURE PATIENTS WITH ABDOMINAL DESMOPLASTIC SMALL ROUND CELL TUMOR? RESULTS OF A RETROSPECTIVE MULTICENTRIC STUDY ON 100 PATIENTS**  
**Charles Honoré**<sup>1</sup>; Jean-Baptiste Delhorme<sup>2</sup>; Elise Nassif<sup>3</sup>; Gwenael Ferron<sup>4</sup>; Emmanuelle Bompas<sup>5</sup>; Olivier Glehen<sup>6</sup>; Antoine Italiano<sup>7</sup>; Francois Bertucci<sup>8</sup>; Daniel Orbach<sup>9</sup>; Axel Le Cesne<sup>3</sup>; Jean-Yves Blay<sup>10</sup>; Christine Chevreau<sup>11</sup>; Olivier Mir<sup>3</sup>  
<sup>1</sup>Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; <sup>2</sup>General and Digestive Surgery, Strasbourg University Hospital, Strasbourg, France; <sup>3</sup>Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; <sup>4</sup>Surgery, Claudius Régaud Institute, Toulouse, France; <sup>5</sup>Medical Oncology, West Cancer Institute, Nantes, France; <sup>6</sup>Surgical Oncology, South Lyon University Hospital, Lyon, France; <sup>7</sup>Medical Oncology, Bergonié Institute, Bordeaux, France; <sup>8</sup>Medical Oncology, Paoli-Calmettes Institute, Marseilles, France; <sup>9</sup>SIREDO, Institut Curie, Paris, France; <sup>10</sup>Medical Oncology, Centre Léon Bérard, Lyon, France; <sup>11</sup>Medical Oncology, Claudius Régaud Institute, Toulouse, France
- Paper 050 3027816  
**ENHANCED RECOVERY AFTER SURGERY (ERAS) IN PATIENTS UNDERGOING SURGERY FOR SOFT TISSUE SARCOMA (STS): EARLY RESULTS OF A PROSPECTIVE QUALITY IMPROVEMENT PROTOCOL**  
**Heather Lyu**<sup>1</sup>; Lily V. Saadat<sup>1</sup>; Elizabeth H. Baldini<sup>2</sup>; Jiping Wang<sup>1</sup>; Matthias Stopfkuchen-Evans<sup>1</sup>; Ronald Bleday<sup>1</sup>; Monica Bertagnolli<sup>1</sup>; Chandrajit Raut<sup>1</sup>  
<sup>1</sup>Brigham and Women's Hospital, Boston, MA, USA; <sup>2</sup>Dana Farber Cancer Institute, Boston, MA, USA
- Paper 051 3042593  
**DEVELOPMENT OF A DYNAMIC PROGNOSTIC NOMOGRAM TO PREDICT OVERALL SURVIVAL DURING FOLLOW-UP IN PRIMARY EXTREMITY SOFT TISSUE SARCOMA PATIENTS TREATED WITH SURGERY**  
**Dario Callegaro**<sup>1</sup>; Rosalba Miceli<sup>2</sup>; Sylvie Bonvalot<sup>3</sup>; Peter Ferguson<sup>4</sup>; Dirk Strauss<sup>5</sup>; Antonin Levy<sup>6</sup>; Anthony M. Griffin<sup>4</sup>; Andrew J. Hayes<sup>5</sup>; Silvia Stacchiotti<sup>7</sup>; Cécile Le Péchoux<sup>6</sup>; Myles J. Smith<sup>5</sup>; Marco Fiore<sup>1</sup>; Angelo Paolo Dei Tos<sup>8</sup>; Henry Smith<sup>5</sup>; Charles Catton<sup>9</sup>; Paolo Casali<sup>10</sup>; Jay Wunder<sup>4</sup>; Alessandro Gronchi<sup>1</sup>  
<sup>1</sup>Surgery, Istituto Nazionale Tumori, Milan, Italy; <sup>2</sup>Clinical Epidemiology and Trial Organisation, Istituto Nazionale Tumori, Milan, Italy; <sup>3</sup>Surgery, Institut Curie, PSL Research University, Paris, France; <sup>4</sup>Surgery, Mount Sinai and Princess Margaret Hospitals, University of Toronto, Toronto, ON, Canada; <sup>5</sup>Surgery, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; <sup>6</sup>Radiation Oncology, Gustave Roussy Cancer Campus, Paris Sud University, Villejuif, France; <sup>7</sup>Cancer Medicine, Istituto Nazionale Tumori, Milan, Italy; <sup>8</sup>Pathology, General Hospital of Treviso, Treviso, Italy; <sup>9</sup>Radiation Oncology, Mount Sinai and Princess Margaret Hospitals, University of Toronto, Toronto, ON, Canada; <sup>10</sup>Oncology and Hemato-Oncology, Istituto Nazionale Tumori, University of Milan, Milan, Italy
- Paper 052 3042509  
**THE IMPACT OF UNPLANNED EXCISIONS OF SOFT TISSUE SARCOMAS: A MULTI-INSTITUTIONAL PROPENSITY SCORE ANALYSIS FROM THE US-SARCOMA COLLABORATIVE**  
**Mohammad Zaidi**<sup>1</sup>; Cecilia G. Ethun<sup>1</sup>; Yuan Liu<sup>2</sup>; Thuy B. Tran<sup>3</sup>; George Poultsides<sup>3</sup>; Valerie P. Grignol<sup>4</sup>; J. H. Howard<sup>4</sup>; Meena Bedi<sup>5</sup>; Harveshp Mogal<sup>6</sup>; Jennifer Tseng<sup>7</sup>; Kevin K. Roggin<sup>7</sup>; Konstantinos Chouliaras<sup>8</sup>; Konstantinos Votanopoulos<sup>8</sup>; Darren Cullinan<sup>9</sup>; Ryan C. Fields<sup>9</sup>; Shervin Oskouei<sup>1</sup>; Nickolas Reimer<sup>1</sup>; David Monson<sup>1</sup>; Kenneth Cardona<sup>1</sup>  
<sup>1</sup>Surgery, Emory University, Atlanta, GA, USA; <sup>2</sup>Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA; <sup>3</sup>Surgery, Stanford University, Atlanta, GA, USA; <sup>4</sup>Surgery, The Ohio State University, Columbus, OH, USA; <sup>5</sup>Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; <sup>6</sup>Surgery, Medical College of Wisconsin, Milwaukee, WI, USA; <sup>7</sup>Surgery, University of Chicago Medicine, Chicago, IL, USA; <sup>8</sup>Surgery, Wake Forest University, Winston-Salem, NC, USA; <sup>9</sup>Surgery, Washington University School of Medicine, St. Louis, MO, USA